Jazz Pharma Announces $100 Million “Green” Manufacturing Plant for Cannabis-Based Medicines

Jazz Pharmaceuticals has broken ground on a new $100 million manufacturing plant for cannabis-based medicines in the UK. The facility will be constructed in Kent Science Park (KSP) in Sittingbourne, an industrial town in Kent, England.

According to a press release from Jazz Pharma, the plant has a planned opening date in 2024 and will welcome 100 new employees. The 60,000-square-foot facility was specially designed to support the company’s two regulatory-approved cannabis-based medicines and offer capacity for future drugs currently under development.